Clinical Implementation Of177lu-Psma-617 in the United States: Lessons Learned and Ongoing Challenges

Praful Ravi,Bridget Whelpley,Emma Kelly,Andrew Wolanski,Jolivette Ritzer,Matthew Robertson,Hina Shah,Alicia K. Morgans,Xiao X. Wei,Rajitha Sunkara, Mark Pomerantz,Mary -Ellen Taplin,Kerry L. Kilbridge,Atish D. Choudhury,Heather Jacene

JOURNAL OF NUCLEAR MEDICINE（2023）

引用 1|浏览12

暂无评分

摘要

In March 2022, 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan) received Food and Drug Administration approval for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men with prostate-specific membrane antigen (PSMA)–avid disease who have received prior chemotherapy and a novel

查看译文

关键词

Metastatic Prostate Cancer,Cancer Treatment,Prostate Cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要